Evaluating Newly Approved Drugs for Multidrug-resistant TB
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
endTB Clinical Trial a Phase III, randomized, controlled, open-label, non-inferiority,
multi-country trial evaluating the efficacy and safety of five new, all-oral, shortened
regimens for multidrug-resistant tuberculosis (MDR-TB).
Phase:
Phase 3
Details
Lead Sponsor:
Médecins Sans Frontières France Médecins Sans Frontières, France
Collaborators:
Epicentre Harvard Medical School Harvard Medical School (HMS and HSDM) Institute of Tropical Medicine, Belgium Interactive Research and Development Ministry of Health, Kyrgyzstan Ministry of Health, Lesotho National Center for Tuberculosis and Lung Diseases, Georgia National Center for Tuberculosis Problems, Kazakhstan Partners in Health Socios En Salud, Peru